Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Wolfspeed reported fiscal third-quarter sales declined and its loss widened as revenue at the chipmaker's Materials Products ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with ...

Can Upcoming US-China Trade Talks Fuel This 'Unloved Rally'? Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates Supermicro Stock Dives as Weak Preliminary Results Raise ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...